- Home
- DXLG vs IMMX Comparison
DXLG vs IMMX Comparison
Compare DXLG & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXLG
- IMMX
- Stock Information
- Founded
- DXLG 1976
- IMMX 2014
- Country
- DXLG United States
- IMMX United States
- Employees
- DXLG N/A
- IMMX N/A
- Industry
- DXLG Clothing/Shoe/Accessory Stores
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- DXLG Consumer Discretionary
- IMMX Health Care
- Exchange
- DXLG Nasdaq
- IMMX Nasdaq
- Market Cap
- DXLG 55.4M
- IMMX 65.5M
- IPO Year
- DXLG 1987
- IMMX 2021
- Fundamental
- Price
- DXLG $1.41
- IMMX $1.96
- Analyst Decision
- DXLG Strong Buy
- IMMX Strong Buy
- Analyst Count
- DXLG 1
- IMMX 1
- Target Price
- DXLG $2.50
- IMMX $8.00
- AVG Volume (30 Days)
- DXLG 216.3K
- IMMX 185.2K
- Earning Date
- DXLG 08-27-2025
- IMMX 11-11-2025
- Dividend Yield
- DXLG N/A
- IMMX N/A
- EPS Growth
- DXLG N/A
- IMMX N/A
- EPS
- DXLG N/A
- IMMX N/A
- Revenue
- DXLG $447,744,000.00
- IMMX N/A
- Revenue This Year
- DXLG N/A
- IMMX N/A
- Revenue Next Year
- DXLG $3.56
- IMMX N/A
- P/E Ratio
- DXLG N/A
- IMMX N/A
- Revenue Growth
- DXLG N/A
- IMMX N/A
- 52 Week Low
- DXLG $0.90
- IMMX $1.26
- 52 Week High
- DXLG $3.10
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- DXLG 56.66
- IMMX 37.05
- Support Level
- DXLG $1.20
- IMMX $2.09
- Resistance Level
- DXLG $1.52
- IMMX $2.34
- Average True Range (ATR)
- DXLG 0.08
- IMMX 0.15
- MACD
- DXLG 0.01
- IMMX -0.01
- Stochastic Oscillator
- DXLG 65.62
- IMMX 4.88
About DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.